Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (381-390 of 743) with videos related to

Pageof 75
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|May 7, 2008
Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100BKlaus Strobel, Reinhard Dummer, Hans C Steinert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
HER3 is a determinant for poor prognosis in melanomaMarkus Reschke, Daniela Mihic-Probst, Edward Htun van der Horst, et al.
Swiss Medical Weekly|February 23, 2016
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanomaReinhard Dummer, Marco Siano, Robert E Hunger, et al.
Journal of the American Academy of Dermatology|May 20, 2014
Primary cutaneous follicle center lymphoma with diffuse CD30 expression: a report of 4 cases of a rare variantWerner Kempf, Dmitry V Kazakov, Arno Rütten, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2013
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsSimone M Goldinger, Lisa Zimmer, Carsten Schulz, et al.
Acta Dermato-Venereologica|April 26, 2018
Aggressive Rare T-cell Lymphomas with Manifestation in the Skin: A Monocentric Cross-sectional Case StudyMarie-Charlotte Brüggen, Katrin Kerl, Eugenia Haralambieva, et al.
Cancer Treatment Reviews|April 19, 2021
Neurological complications of cancer immunotherapyPatrick Roth, Sebastian Winklhofer, Antonia M S Müller, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2010
Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patientsNatko Nuber, Alessandra Curioni-Fontecedro, Claudia Matter, et al.
Blood|May 27, 2004
Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomasReinhard Dummer, Jessica C Hassel, Friederike Fellenberg, et al.
Oncology Reports|May 23, 2012
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07Peter Schraml, Adriana von Teichman, Daniela Mihic-Probst, et al.
Pageof 75

Showing results (381-390 of 743) with videos related to

Sort By:
Pageof 75
European Journal of Nuclear Medicine and Molecular Imaging|May 7, 2008
Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100BKlaus Strobel, Reinhard Dummer, Hans C Steinert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
HER3 is a determinant for poor prognosis in melanomaMarkus Reschke, Daniela Mihic-Probst, Edward Htun van der Horst, et al.
Swiss Medical Weekly|February 23, 2016
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanomaReinhard Dummer, Marco Siano, Robert E Hunger, et al.
Journal of the American Academy of Dermatology|May 20, 2014
Primary cutaneous follicle center lymphoma with diffuse CD30 expression: a report of 4 cases of a rare variantWerner Kempf, Dmitry V Kazakov, Arno Rütten, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2013
Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsSimone M Goldinger, Lisa Zimmer, Carsten Schulz, et al.
Acta Dermato-Venereologica|April 26, 2018
Aggressive Rare T-cell Lymphomas with Manifestation in the Skin: A Monocentric Cross-sectional Case StudyMarie-Charlotte Brüggen, Katrin Kerl, Eugenia Haralambieva, et al.
Cancer Treatment Reviews|April 19, 2021
Neurological complications of cancer immunotherapyPatrick Roth, Sebastian Winklhofer, Antonia M S Müller, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2010
Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patientsNatko Nuber, Alessandra Curioni-Fontecedro, Claudia Matter, et al.
Blood|May 27, 2004
Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomasReinhard Dummer, Jessica C Hassel, Friederike Fellenberg, et al.
Oncology Reports|May 23, 2012
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07Peter Schraml, Adriana von Teichman, Daniela Mihic-Probst, et al.
Pageof 75